Companies: 10,795·Total market cap: $144.5T
BeOne Medicines Ltd.

BeOne Medicines Ltd.

ONCNASDAQHealthcare● Active
$271.13
+$1.03(+0.38%)
Market Cap$29.0B
P/E Ratio
52W High$385.22
52W Low$239.25

BeOne Medicines Ltd. (ONC) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

onc · stock forecast · 14 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 14 Wall Street analysts in the past 3 months

SellBuy

Buy

14 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
13
Hold
1
Sell
0
Strong Sell
0
Total: 14 · Buy rate: 92.9%

12-Month Price Target

High

$436

Consensus

$399

+47.3% upside

Low

$340

Median: $409 · Last Close: $270.97

The BeOne Medicines Ltd. (ONC) analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month ONC price target is $399.11, representing +47.3% upside from the current price of $270.97.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $399 (47.3%)

Consensus Target

$399.11

47.3% upside

High Target

$436

60.9%

Low Target

$340

25.5%

Current Price

$270.97

as of today

Based on analyst price targets, the ONC stock price prediction for the next 12 months ranges from $340 to $436. The consensus ONC price forecast of $399.11 implies 47.3% upside from the current price of $270.97.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$258.774.50%

1-day model range: $257.75–$259.78. Peak: $259.78 (-4.50%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$305+12.7%
2028$330+21.9%
2029$348+28.4%
2030$360+32.9%
2031+35.9%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

0%7%93%
0Buy
1Neutral
13Sell
RSI (14)33.9Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · ONC · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$274.94SELL
MA 10$283.53SELL
MA 20$294.71SELL
MA 50$301.14SELL
MA 100$313.09SELL
MA 200$320.15SELL
Current $ONC · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$275.67SELL
EMA 10$282.08SELL
EMA 20$289.80SELL
EMA 50$298.90SELL
EMA 100$306.09SELL
EMA 200$304.09SELL
Current $ONC · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
RBC Capital2026-06-02
Maintains
OutperformOutperform
Leerink Partners2026-05-15
Maintains
OutperformOutperform
Guggenheim2026-05-07
Maintains
BuyBuy
RBC Capital2026-05-07
Maintains
OutperformOutperform
Barclays2026-05-07
Maintains
OverweightOverweight
Truist Securities2026-05-07
Maintains
BuyBuy
Jefferies2026-03-16
Downgrade ↓
BuyHold
RBC Capital2026-02-27
Maintains
OutperformOutperform
Guggenheim2026-02-27
Maintains
BuyBuy
Barclays2026-02-27
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on BeOne Medicines Ltd. (ONC) stock. Of the recent 38 rating actions, 0 were upgrades and 1 were downgrades. 14 analysts currently cover ONC.

Analyst Recommendation Trends

Buy ratings211
Hold ratings00
Sell ratings00

ONC analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$6.5B

↓ 23.5% YoY

Revenue Next Year

$7.5B

↑ 15.4% YoY

EPS This Year

$6.73

EPS Next Year

$9.79

↑ 45.4% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ONC EPS of $6.73 for the current fiscal year, based on estimates from 12 analysts. The ONC revenue forecast is $6.5B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ONC stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ONC price target is $399.11 (+47.3% upside), with an analyst consensus of Buy.

The ONC short-term stock prediction for tomorrow is $258.77 (-4.50%). The ONC stock price prediction for 2027 estimates an average of $305. The ONC stock prediction for 2030 projects a range of $345–$376.

BeOne Medicines Ltd. trades on NASDAQ under the ticker ONC. The ONC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 93% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ONC forecast · 8 questions

According to 14 Wall Street analysts, the average 12-month ONC price target is $399.11, with a high forecast of $436.00 and a low of $340.00. The median price target is shown in the chart above when available. This implies +47.3% potential upside from the current price of $270.97.

ONC price targetWhat is ONC price targetONC analyst price targetONC 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.